Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2014 Sep;20(9):1274-81. doi: 10.1016/j.bbmt.2014.03.017. Epub 2014 Mar 27.

Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.

Author information

1
Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
2
Stanford University School of Medicine, Palo Alto, California.
3
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
4
University Medical Center, Hamburg, Germany.
5
University of Illinois College of Medicine at Chicago, Chicago, Illinois.
6
Leukemia Department, MD Anderson Cancer Center, Houston, Texas.
7
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address: blarson@fhcrc.org.

Abstract

Myelofibrosis (MF) is a manifestation of several disorders of hematopoiesis, collectively referred to as myeloproliferative neoplasms. Allogeneic hematopoietic stem cell transplantation (ASCT) is the only therapy with proven curative potential. However, most patients with MF are in their 6th or 7th decade of life, and only some of these patients have been considered suitable transplantation candidates. The development of reduced-intensity conditioning regimens with limited toxicity has allowed clinicians to offer ASCT to a growing number of older patients. The availability of Janus Kinase (JAK) 1/2 inhibitors allows clinicians to provide symptom relief and improved quality of life for MF patients. These drugs may also affect the decision regarding, in particular, the timing of ASCT. Future studies need to address the role of JAK1/2 inhibitors in patients who are transplantation candidates and determine their role before and, possibly, after transplantation. The identification of indications for the use of JAK1/2 inhibitors in the context of transplantation may lead to new therapeutic strategies for patients with MF.

KEYWORDS:

Homologous; INCB018424; Janus Kinase 1; Primary myelofibrosis; Transplantation

PMID:
24680977
PMCID:
PMC4465357
DOI:
10.1016/j.bbmt.2014.03.017
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center